Evidence map›Paper›PMID 33125442›Full record

ArticlePloS one2020

Perspectives of cancer patients and their health during the COVID-19 pandemic.

Emil Lou, Deanna Teoh, Katherine Brown, Anne Blaes, Shernan G Holtan, Patricia Jewett, Helen Parsons, E Waruiru Mburu, Lauren Thomaier, Jane Yuet Ching Hui and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 3 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 3 syntheses or guidelines pooled it, 87 citations in OpenAlex.

  1. Pooled it
  2. Counting the social, psychological, and economic costs of COVID-19 for cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Pooled it
  3. Pooled it
  4. A Demographic Look at Cancer Treatment Behaviors during the COVID-19 Pandemic.medRxiv : the preprint server for health sciences · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. The experience of cancer patients during the COVID-19 pandemic.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2023
    Article
  18. Article
  19. Article
  20. Cancer Patients during COVID-19 Pandemic: A Mini-Review.Healthcare (Basel, Switzerland) · 2023
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Emil LouDivision of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota, United States of America.ORCID 0000-0002-1607-1386
Deanna TeohMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States of America.
Katherine BrownDepartment of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, Minnesota, United States of America.
Anne BlaesDivision of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota, United States of America.
Shernan G HoltanDivision of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota, United States of America.
Patricia JewettDivision of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota, United States of America.
Helen ParsonsMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States of America.
E Waruiru MburuDivision of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, United States of America.
Lauren ThomaierDepartment of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, Minnesota, United States of America.
Jane Yuet Ching HuiMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States of America.ORCID 0000-0002-2628-0720
Heather H NelsonMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States of America.
Rachel I VogelMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States of America.
University of Minnesota · US

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Jeffrey S. Miller · 1998 to 2026
$100.4M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
NCATS NIH HHS UL1 TR002494NCI NIH HHS P30 CA077598
6 · The paper itself

Abstract

introductionThe immunosuppressive nature of some cancers and many cancer-directed treatments may increase the risk of infection with and severe sequelae from Coronavirus Disease 2019 (COVID-19). The objective of this study was to compare concerns about COVID-19 among individuals undergoing cancer treatment to those with a history of cancer not currently receiving therapy and to those without a cancer history.

methodsWe conducted a cross-sectional anonymous online survey study of adults currently residing in the United States. Participants were recruited over a one-week period (April 3-11, 2020) using promoted advertisements on Facebook and Twitter. Groups were compared using chi-squared tests, Fisher's exact tests, and t-tests.

results543 respondents from 47 states provided information on their cancer history and were included in analyses. Participants receiving active treatment reported greater concern about infection from the SARS-CoV-2 coronavirus (p<0.001), higher levels of family distress caused by the COVID-19 pandemic (p = 0.004), and greater concern that the general public does not adequately understand the seriousness of COVID-19 (p = 0.04). Those with metastatic disease were more likely to indicate that COVID-19 had negatively affected their cancer care compared to patients with non-metastatic cancer (50.8% vs. 31.0%; p = 0.02). The most commonly reported treatment modifications included chemotherapy delays.

conclusionsPatients undergoing active treatment for cancer were most concerned about the short-term effects of the COVID-19 pandemic on the logistics as well as potential efficacy of ongoing cancer treatment, longer term effects, and overarching societal concerns that the population at large is not as concerned about the public health implications of SARS-CoV-2 infection.

Indexed as

AdultCOVID-19Cross-Sectional StudiesFemaleHumansMaleNeoplasmsPublic HealthSARS-CoV-2Surveys and QuestionnairesUnited States

Identifiers

PMID33125442
PMCPMC7598454
OpenAlexW3097741487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.